Form 4 for APRE Aprea Therapeutics, Inc.
Accepted 2024-03-14 00:00:00 ET · period of report 2024-03-13 · accession 0001104659-24-034671 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-14 | 2024-03-13 | APRE | HENNEMAN JOHN B III | Dir | P - Purchase | $7.29 | +6,860 | 8,139 | +536% | +$50.0K |
| DM | 2024-03-14 | 2024-03-13 | APRE | HENNEMAN JOHN B III | Dir | P - Purchase | — | +6,860 | 3,430 | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-13 | P | A | 6,860 | $7.29 | 8,139 | D | — | — | |
| 2 | Derivative | Tranche A Warrant | 2024-03-13 | P | A | 3,430 | — | 3,430 | D | — · 2024-03-13 to — | 3,430 Common Stock | (F3) The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above. (F1) The exercise price of the Tranche A Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share. (F2) Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred. |
| 3 | Derivative | Tranche B Warrant | 2024-03-13 | P | A | 3,430 | — | 3,430 | D | — · 2024-03-13 to — | 3,430 Common Stock | (F6) The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above. (F4) The exercise price of the Tranche B Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share. (F5) Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred. |